Oxaliplatin and bevacizumab disappoint for rectal cancer
The addition of bevacizumab and oxaliplatin to standard neoadjuvant chemoradiotherapy does not enhance clinical response rates in rectal cancer, show phase II study results.
Source: MedWire News - Gastroenterology - Category: Gastroenterology Source Type: news
More News: Avastin | Cancer | Cancer & Oncology | Eloxatin | Gastroenterology | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Rectal Cancers | Study